2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2019
Factors Associated With Adherence to Helicobacter pylori Testing During Hospitalization for Bleeding Peptic Ulcer Disease
Hung KW, Knotts RM, Faye AS, Pont AR, Lebwohl B, Abrams JA, Freedberg DE. Factors Associated With Adherence to Helicobacter pylori Testing During Hospitalization for Bleeding Peptic Ulcer Disease. Clinical Gastroenterology And Hepatology 2019, 18: 1091-1098.e1. PMID: 31352090, DOI: 10.1016/j.cgh.2019.07.037.Peer-Reviewed Original ResearchConceptsPeptic ulcer diseaseIntensive care unitH pyloriUlcer diseaseGastrointestinal bleedingDuodenal ulcerPylori infectionKaplan-Meier analysisH pylori infectionHelicobacter pylori infectionYear of admissionHelicobacter pylori testingElectronic medical recordsEvidence of testsIndex endoscopyCoagulation statusComposite outcomeEndoscopic factorsBlood lossHospital admissionCare unitRetrospective studyMedical recordsMultivariable modelUlcer severity